Rani Therapeutics

50 articles with Rani Therapeutics

• Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update

  3/22/2023

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2022 and provided a corporate update.

• Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

  3/16/2023

  Rani Therapeutics Holdings, Inc. announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Wednesday, March 22 after the close of trading.

• Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment

  1/9/2023

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has partnered with Celltrion for the development of RT-111, an orally administered ustekinumab biosimilar.

• Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update

  1/5/2023

  Rani Therapeutics Holdings, Inc. announced that it completed a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration with respect to RT-102, the RaniPill™ GO containing a proprietary formulation of human parathyroid hormone analog for the potential treatment of osteoporosis, and provided a corporate update.

• Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study

  12/6/2022

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced topline results from Part 2 (repeat-dose portion) of the Phase 1 study of RT-102, the RaniPill™ GO capsule containing a proprietary formulation of human parathyroid hormone (1-34) analog (PTH) being developed for the treatment of osteoporosis.

• Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/10/2022

  Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, reported financial results for the quarter ended September 30, 2022, and provided a corporate update.

• Rani Therapeutics to Present at the 2022 Stifel Healthcare Conference

  11/9/2022

  Rani Therapeutics Holdings, Inc., a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced that the company will present at the Stifel Healthcare Conference taking place on November 15 - 16, 2022.

• Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update

  10/24/2022

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the preclinical development of RT-111, a RaniPill GO capsule containing an ustekinumab biosimilar, as part of a corporate and pipeline update.

• Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Rani Therapeutics Holdings, Inc. announced that the company will present at the H.C. Wainwright Global Investment Conference, taking place September 12 - 14, 2022 virtually and in-person.

• 

  Clinical Catch-Up: Amgen's Mixed Lumakras Data for Lung Cancer and More

  8/15/2022

  Amgen announced two lung cancer studies with mixed results, Innovent dosed the first patient in a Phase I diabetic macular edema study and HUTCHMED hit the primary endpoint in colorectal cancer.

• Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock - Aug 12, 2022

  8/12/2022

  Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced that it has terminated the underwritten public offering of its Class A common stock previously announced on August 10, 2022.

• Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update

  8/10/2022

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”, “the Company” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

• Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock - Aug 10, 2022

  8/10/2022

  Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics, announced that it intends to offer and sell shares of its Class A common stock in an underwritten public offering.

• Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis

  8/10/2022

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), today announced positive topline results from the single-ascending dose portion of its Phase 1 clinical study of RT-102, a RaniPill capsule containing a proprietary formulation of human parathyroid hormone (PTH) analog PTH (1-34) for the potential treatment of osteoporosis (“Study Part 1”).

• Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill® Platform Advancement and Clinical Pipeline DevelopmentExtends Rani’s projected cash runway into mid-2024

  8/8/2022

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today announced that it has entered into a loan agreement with Avenue Venture Opportunities Fund, L.P. (“Avenue”) for up to $45 million of funding.

• Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update

  5/11/2022

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

• Rani Therapeutics to Present at Upcoming Investor Conferences in May 2022

  5/3/2022

  Rani Therapeutics Holdings, Inc., a clinical stage biotherapeutics company focused on the oral delivery of biologics, announced that the company’s Chief Executive Officer, Talat Imran, will present at two upcoming investor conferences in May.

• Rani Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/7/2022

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 12:45 p.m. PT / 3:45 p.m. ET.

• 

  Rani is Opening Doors in Biosimilars, Challenging Humira and Others

  3/31/2022

  San Jose-based Rani Therapeutics reported its fourth quarter and full-year 2021 financial results. The company hit major milestones this year, including the recent launch of the RaniPill High Capacity,

• Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update

  3/29/2022

  Rani Therapeutics Holdings, Inc., a clinical stage biotherapeutics company focused on the oral delivery of biologics, reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.